11,615
Views
48
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE: Breast Cancer

Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study

, , , , , & show all
Pages 188-192 | Received 04 May 2015, Accepted 03 Jun 2015, Published online: 04 Aug 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Andrea R. Genazzani, Patrizia Monteleone, Andrea Giannini & Tommaso Simoncini. (2021) Pharmacotherapeutic options for the treatment of menopausal symptoms. Expert Opinion on Pharmacotherapy 22:13, pages 1773-1791.
Read now
Ola A. M. Omar & Ayman Ewies. (2021) Re: The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen. Journal of Obstetrics and Gynaecology 41:2, pages 332-332.
Read now
J. Bitzer. (2019) Overview of perimenopausal contraception. Climacteric 22:1, pages 44-50.
Read now
Placido Llaneza, Joaquim Calaf, Ana Rosa Jurado, Nicolas Mendoza, Borja Otero, Francisco Quereda, Rafael Sánchez-Borrego & Daniel Lubian. (2018) What do TSECs provide in the menopausal hormone therapy?. Gynecological Endocrinology 34:10, pages 826-832.
Read now
Norman D. Goldstuck & Hung P. Le. (2018) Delivery of progestins via the subdermal versus the intrauterine route: comparison of the pharmacology and clinical outcomes. Expert Opinion on Drug Delivery 15:7, pages 717-727.
Read now

Articles from other publishers (42)

Renate Louw-du Toit, Mishkah Simons & Donita Africander. (2023) Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology, pages 106440.
Crossref
Srirupa Ghosh, Rachel Imrie, James Goadsby & Michael Savvas. (2023) A focus on progestogens in hormone replacement therapy. The Obstetrician & Gynaecologist 25:4, pages 263-271.
Crossref
Meghan Cartwright, Renate Louw-du Toit, Hayley Jackson, Melani Janse van Vuuren & Donita Africander. (2023) Progesterone receptor isoform ratios influence the transcriptional activity of progestins via the progesterone receptor. The Journal of Steroid Biochemistry and Molecular Biology 232, pages 106348.
Crossref
Mei Heting, Lu Wenping, Wang Yanan, Zhang Dongni, Wu Xiaoqing & Zhuo Zhli. (2023) Levonorgestrel intrauterine system and breast cancer risk: An updated systematic review and meta-analysis of observational studies. Heliyon 9:4, pages e14733.
Crossref
. (2023) FSRH Guideline (March 2023) Intrauterine contraception. BMJ Sexual & Reproductive Health 49:Suppl 1, pages 1-142.
Crossref
Salvatore Giovanni Vitale, Luigi Della Corte, Michał Ciebiera, Josè Carugno, Gaetano Riemma, Ricardo Bassil Lasmar, Bernardo Portugal Lasmar, Ilker Kahramanoglu, Bulent Urman, Mislav Mikuš, Carlo De Angelis, Péter Török & Stefano Angioni. (2023) Hysteroscopic Endometrial Ablation: From Indications to Instrumentation and Techniques—A Call to Action. Diagnostics 13:3, pages 339.
Crossref
Aline Zürcher & Petra Stute. (2022) Levonorgestrelhaltige Hormonspirale und MammakarzinomrisikoLevonorgestrel-releasing intrauterine system and the risk of breast cancer. Gynäkologische Endokrinologie 20:4, pages 285-287.
Crossref
Aline Zürcher, Laura Knabben, Heidrun Janka & Petra Stute. (2022) Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review. Archives of Gynecology and Obstetrics 307:6, pages 1747-1761.
Crossref
Sushmita Katuwal, Juha Tapanainen & Eero Pukkala. (2022) Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer. Breast Cancer Research and Treatment 193:2, pages 495-505.
Crossref
Ghada Mohammed, Noha A. Mousa, Iman M. Talaat, Haya Ibrahim & Maha Saber-Ayad. (2021) Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling. Frontiers in Endocrinology 12.
Crossref
Johannes Bitzer. 2021. The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology. The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology 161 169 .
Fabio R. Silva, Antonio Jose Grande, Ana Cristina Lacerda Macedo, Tamy Colonetti, Marina C. Rocha, Maria Laura Rodrigues Uggioni, Bruno R. Silva & Maria Inês da Rosa. (2021) Meta-Analysis of Breast Cancer Risk in Levonorgestrel-Releasing Intrauterine System Users. Clinical Breast Cancer 21:6, pages 497-508.
Crossref
C. Ángel-Parra, A.M. Pascual-Domenech & E. González-Mirasol. (2021) Riesgo de cáncer de mama en portadoras de DIU de levonorgestrel. Revisión sistemática. Clínica e Investigación en Ginecología y Obstetricia 48:4, pages 100668.
Crossref
Marie Shamseddin, Fabio De Martino, Céline Constantin, Valentina Scabia, Anne‐Sophie Lancelot, Csaba Laszlo, Ayyakkannu Ayyannan, Laura Battista, Wassim Raffoul, Marie‐Christine Gailloud‐Matthieu, Philipp Bucher, Maryse Fiche, Giovanna Ambrosini, George Sflomos & Cathrin Brisken. (2021) Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. EMBO Molecular Medicine 13:7.
Crossref
Hiroshi Kobayashi. 2021. Hereditary Breast and Ovarian Cancer. Hereditary Breast and Ovarian Cancer 149 167 .
Philip C. Hannaford & Lisa Iversen. 2021. Female and Male Contraception. Female and Male Contraception 161 194 .
Johannes Bitzer. 2021. Progestogens in Obstetrics and Gynecology. Progestogens in Obstetrics and Gynecology 117 136 .
Norman D. Goldstuck. (2020) Modern menstruation: Is it abnormal and unhealthy?. Medical Hypotheses 144, pages 109955.
Crossref
Anne Gompel. (2020) Progesterone and endometrial cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 69, pages 95-107.
Crossref
Caroline A. Lamb, Victoria T. Fabris & Claudia Lanari. (2020) Progesterone and breast. Best Practice & Research Clinical Obstetrics & Gynaecology 69, pages 85-94.
Crossref
Britton Trabert, Mark E Sherman, Nagarajan Kannan & Frank Z Stanczyk. (2020) Progesterone and Breast Cancer. Endocrine Reviews 41:2, pages 320-344.
Crossref
Isaac Manyonda, Vikram S Talaulikar, Roxanna Pirhadi & Joseph Onwude. (2019) Progestogens are the problem in hormone replacement therapy: Time to reappraise their use. Post Reproductive Health 26:1, pages 26-31.
Crossref
Katrine Yare & Michael Woodward. (2020) Hormone Therapy and Effects on Sporadic Alzheimer’s Disease in Postmenopausal Women: Importance of Nomenclature. Journal of Alzheimer's Disease 73:1, pages 23-37.
Crossref
Johannes Bitzer. 2020. Obesity and Gynecology. Obesity and Gynecology 67 73 .
Anne Gompel. (2019) Hormones et cancers du sein. La Presse Médicale 48:10, pages 1085-1091.
Crossref
Shira Rebecca Saul & Nathan Kase. (2018) Aging, the menopausal transition, and hormone replenishment therapy: retrieval of confidence and compliance. Annals of the New York Academy of Sciences 1440:1, pages 5-22.
Crossref
Ya. Z. Zaidieva. (2019) The effect of progesterone, progestins, and menopausal hormone therapy on the endometrium in peri- and postmenopause. Rossiiskii vestnik akushera-ginekologa 19:2, pages 57.
Crossref
Courtney A. Schreiber & Kurt Barnhart. 2019. Yen and Jaffe's Reproductive Endocrinology. Yen and Jaffe's Reproductive Endocrinology 962 978.e4 .
Rebecca Schneyer & Klaira Lerma. (2018) Health outcomes associated with use of hormonal contraception: breast cancer. Current Opinion in Obstetrics & Gynecology 30:6, pages 414-418.
Crossref
William V. Williams, Louise A. Mitchell, S. Kathleen Carlson & Kathleen M. Raviele. (2019) Association of Combined Estrogen–Progestogen and Progestogen-Only Contraceptives with the Development of Cancer. The Linacre Quarterly 85:4, pages 412-452.
Crossref
Carolyn L. Westhoff & Malcolm C. Pike. (2018) Hormonal contraception and breast cancer. Contraception 98:3, pages 171-173.
Crossref
Carolyn L. Westhoff & Malcolm C. Pike. (2018) Hormonal contraception and breast cancer. American Journal of Obstetrics and Gynecology 219:2, pages 169.e1-169.e4.
Crossref
Cheryl Phua & Rodney Baber. (2018) The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview. Drugs & Aging 35:8, pages 699-705.
Crossref
Taniqua A. Miller, Rebecca H. Allen, Andrew M. KaunitzCarrie A. Cwiak. (2018) Contraception for midlife women: a review. Menopause 25:7, pages 817-827.
Crossref
Rishil J. Kathawala, Andrzej Kudelka & Basil Rigas. (2018) The Chemoprevention of Ovarian Cancer: the Need and the Options. Current Pharmacology Reports 4:3, pages 250-260.
Crossref
Mie Jareid, Jean-Christophe Thalabard, Morten Aarflot, Hege M. Bøvelstad, Eiliv Lund & Tonje Braaten. (2018) Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecologic Oncology 149:1, pages 127-132.
Crossref
Nava Siegelmann-Danieli, Itzhak Katzir, Janet Vesterman Landes, Yaakov Segal, Rachel Bachar, Hadas Rotem Rabinovich, Martin Bialik, Joseph Azuri, Avi Porath & Yossef Lomnicky. (2017) Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast Cancer Research and Treatment 167:1, pages 257-262.
Crossref
Merete Ellingjord-Dale, Linda Vos, Steinar Tretli, Solveig Hofvind, Isabel dos-Santos-Silva & Giske Ursin. (2017) Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Breast Cancer Research 19:1.
Crossref
Jo Marsden. (2017) Hormonal contraception and breast cancer, what more do we need to know?. Post Reproductive Health 23:3, pages 116-127.
Crossref
Tuuli Soini, Matti Rantanen, Jorma Paavonen, Seija Grénman, Johanna Mäenpää, Eero Pukkala, Mika Gissler & Ritva Hurskainen. (2017) Long-term Follow-up After Endometrial Ablation in Finland. Obstetrics & Gynecology 130:3, pages 554-560.
Crossref
Susanne Schüler-Toprak, Stephan Seitz & Olaf Ortmann. (2017) Hormones and risk of breast and gynecological cancerHormone und das Risiko für Brustkrebs und gynäkologische Malignome. Der Gynäkologe 50:1, pages 43-54.
Crossref
Douwe A. A. Verkuyl. (2016) Recent developments have made female permanent contraception an increasingly attractive option, and pregnant women in particular ought to be counselled about it. Contraception and Reproductive Medicine 1:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.